Intercept Pharmaceuticals’ (ICPT) Positive Rating Reaffirmed at Leerink Swann
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)‘s stock had its “positive” rating reaffirmed by stock analysts at Leerink Swann in a research report issued to clients and investors on Friday.
Several other analysts have also recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $239.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, October 7th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Robert W. Baird reaffirmed an “outperform” rating and issued a $332.00 target price on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Credit Suisse Group AG reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, September 22nd. Finally, JMP Securities reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Thursday, August 18th. Five investment analysts have rated the stock with a sell rating, four have given a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $177.67.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 2.14% during mid-day trading on Friday, hitting $147.18. 35,369 shares of the stock traded hands. The stock’s market cap is $3.64 billion. The company has a 50 day moving average of $155.80 and a 200-day moving average of $151.15. Intercept Pharmaceuticals has a 12-month low of $89.76 and a 12-month high of $217.99.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/intercept-pharmaceuticals-icpt-positive-rating-reaffirmed-at-leerink-swann.html
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.69) by $0.55. The firm had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. Intercept Pharmaceuticals had a negative net margin of 5,003.95% and a negative return on equity of 50.58%. The firm’s revenue was up 1140.4% compared to the same quarter last year. During the same quarter last year, the company earned ($1.99) earnings per share. Equities research analysts forecast that Intercept Pharmaceuticals will post ($16.31) earnings per share for the current year.
In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 35,000 shares of the business’s stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the sale, the chief executive officer now directly owns 579,314 shares in the company, valued at approximately $95,586,810. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lisa Bright sold 246 shares of the business’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $159.00, for a total transaction of $39,114.00. Following the sale, the insider now owns 18,460 shares in the company, valued at $2,935,140. The disclosure for this sale can be found here. Company insiders own 9.20% of the company’s stock.
Several large investors have recently modified their holdings of ICPT. CENTRAL TRUST Co bought a new stake in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $107,000. Legal & General Group Plc raised its stake in Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares in the last quarter. Metropolitan Life Insurance Co. NY raised its stake in Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 38 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Intercept Pharmaceuticals during the second quarter valued at approximately $180,000. Finally, IBM Retirement Fund raised its stake in Intercept Pharmaceuticals by 3.6% in the second quarter. IBM Retirement Fund now owns 1,657 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 58 shares in the last quarter. Institutional investors own 81.86% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.